Thousands of patients who used popular weight loss and diabetes drugs are now pursuing legal claims after developing a debilitating digestive condition called gastroparesis. If you’ve experienced severe nausea, vomiting, or stomach paralysis while taking Ozempic, Wegovy, or similar GLP-1 drugs, you may be entitled to significant compensation.
Our experienced attorneys at Wagstaff & Cartmell are evaluating GLP-1 gastroparesis claims nationwide. Contact us today for a confidential consultation at no cost to you.
What Is Gastroparesis?
Gastroparesis, often referred to as “stomach paralysis,” is a condition where the stomach cannot empty itself of food in a normal manner. In a healthy digestive system, strong muscular contractions move food through the digestive tract. With gastroparesis, these muscle movements slow down or stop working altogether, causing food to remain in the stomach for abnormally long periods.
For patients taking GLP-1 receptor agonists like Ozempic and Wegovy, this condition can develop suddenly and severely. The drugs are designed to slow gastric emptying as part of their therapeutic mechanism; this delay helps patients feel fuller longer and aids in blood sugar control. However, in some patients, this slowing effect becomes excessive and potentially permanent, resulting in a medical condition that can dramatically diminish quality of life.
Unlike temporary digestive upset, gastroparesis is a serious medical diagnosis that requires objective testing to confirm. Many patients describe the condition as feeling like their stomach has simply stopped working, leaving them unable to eat normally or maintain proper nutrition.
How Do GLP-1 Drugs Cause Stomach Paralysis?
GLP-1 (glucagon-like peptide-1) receptor agonists work by mimicking a naturally occurring hormone that regulates blood sugar and appetite. These medications intentionally slow the rate at which food leaves the stomach to help patients feel satisfied with smaller portions and to prevent blood sugar spikes after meals.
In most patients, this delayed emptying is temporary and reversible. However, emerging evidence suggests that some individuals experience a severe and potentially irreversible form of this slowing effect.
The Science Behind the Risk
A groundbreaking observational study published in medical literature found that patients using GLP-1 drugs faced a 3.7 times increased risk of developing gastroparesis compared to those not taking these medications. This statistically significant elevation in risk has prompted widespread concern among gastroenterologists and legal experts alike.
The mechanism appears to involve overstimulation of GLP-1 receptors in the gastrointestinal tract, which can lead to:
- Prolonged inhibition of gastric motility
- Disruption of the normal migrating motor complex
- Potential nerve damage affecting stomach muscle contractions
- Chronic inflammation of the stomach lining
What makes this particularly concerning is that manufacturers allegedly failed to adequately warn patients and physicians about this risk, despite having access to clinical trial data and post-marketing surveillance reports that suggested these severe health complications were occurring at concerning rates.
Symptoms and Injuries: Beyond Simple Nausea
Gastroparesis caused by GLP-1 medications presents with a constellation of symptoms that can range from uncomfortable to life-threatening. Patients report a sudden onset of digestive problems that persist even after discontinuing the medication. Common symptoms include:
- Persistent nausea and vomiting: Often occurring several hours after eating, with vomiting of undigested food
- Severe stomach pain and bloating: A feeling of uncomfortable fullness even after small meals
- Early satiety: Feeling full after eating only a few bites
- Acid reflux and heartburn: Worsening GERD symptoms
- Unpredictable blood sugar fluctuations: Particularly problematic for diabetic patients
- Unintended weight loss: Beyond the intended therapeutic effect
Serious Health Complications Requiring Medical Intervention:
Many patients have required hospitalization due to:
- Severe dehydration: From persistent vomiting and inability to keep fluids down
- Malnutrition: Inability to maintain adequate caloric and nutritional intake
- Ileus: Complete cessation of intestinal motility requiring emergency care
- Bowel obstruction: Food accumulation leading to dangerous blockages
- Aspiration pneumonia: From inhaling vomited stomach contents
- Electrolyte imbalances: Leading to cardiac complications and organ dysfunction
Some patients report that these symptoms have persisted for months or even years after stopping the medication, suggesting permanent damage to the digestive system. The chronic nature of this condition often requires ongoing medical management, dietary restrictions, and in severe cases, surgical interventions such as feeding tube placement.
The Diagnostic Requirement: Gastric Emptying Study
Not every case of nausea or digestive upset qualifies as gastroparesis under the current litigation framework. On August 19, 2025, Judge Karen Marston, who presides over the GLP-1 MDL, issued a critical ruling establishing specific diagnostic criteria for gastroparesis claims.
What the Ruling Requires
Judge Marston’s order mandates that all plaintiffs alleging gastroparesis must have undergone a gastric emptying study, an objective medical test that measures how quickly food moves out of the stomach. This diagnostic requirement ensures that claims are based on verifiable medical evidence rather than subjective symptoms alone. This study typically involves:
- Consuming a standardized meal containing a small amount of radioactive material
- Lying under a scanner that tracks the movement of the meal through your digestive system
- Measurements taken at regular intervals (usually 1, 2, 3, and 4 hours after eating)
- Calculation of the percentage of food remaining in the stomach at each time point
Why This Matters for Your Case
If you experienced severe digestive symptoms while taking a GLP-1 drug but never had one of these studies performed, you may not currently qualify for inclusion in the MDL. However, if your symptoms persist, you should consult with both a gastroenterologist and an experienced Ozempic stomach paralysis lawyer to discuss your options.
Some patients who discontinued their medication before getting tested may still be able to obtain such a study if symptoms continue. Documentation of your symptoms, emergency room visits, hospitalizations, and physician notes describing gastroparesis-like symptoms can still be valuable in building your case.
GLP-1 Drugs Implicated in Gastroparesis Claims
The gastroparesis litigation encompasses multiple GLP-1 receptor agonist medications marketed by several pharmaceutical manufacturers. These drugs were approved for type 2 diabetes management and, in some cases, weight loss in obese or overweight patients.
Medications Named in Gastroparesis Stomach Paralysis Lawsuits
Novo Nordisk products include:
- Ozempic (semaglutide) – for type 2 diabetes treatment
- Wegovy (semaglutide) – for weight management
- Rybelsus (oral semaglutide) – for type 2 diabetes treatment
- Saxenda (liraglutide) – for weight management
Eli Lilly products include:
- Trulicity (dulaglutide) – for type 2 diabetes treatment
- Mounjaro (tirzepatide) – for type 2 diabetes treatment
- Zepbound (tirzepatide) – for weight management
AstraZeneca is another manufacturer, and they produce Byetta (exenatide) for type 2 diabetes management. All of these medications work through similar mechanisms and carry similar risks for serious health complications. Patients who took any of these drugs as prescribed and subsequently developed confirmed gastroparesis may have valid legal claims against the manufacturers.
MDL 3094 Status: Where the Litigation Stands
The GLP-1 gastroparesis stomach paralysis lawsuits have been consolidated into a federal multidistrict litigation (MDL) to streamline the legal process and avoid duplicative discovery across multiple courts. Key details include:
- MDL Number: 3094
- Court: United States District Court for the Eastern District of Pennsylvania
- Presiding Judge: The Honorable Karen S. Marston
- Case Name: In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
- Current Case Count: Thousands of cases filed and continuing to grow monthly
Current Phase and Timeline
The litigation is currently in the pretrial discovery phase, where both plaintiffs and defendants exchange evidence, take depositions, and prepare for potential bellwether trials. Judge Marston has established case management orders to move the litigation forward efficiently.
What to Expect:
- Discovery Period: Ongoing through 2026, with extensive document production and expert witness designations
- Bellwether Trial Selection: Expected in late 2026 or early 2027, where representative cases will go to trial to help gauge fair settlement values
- Settlement Negotiations: Often occur after initial bellwether verdicts, though settlements may happen earlier if defendants choose to negotiate
The MDL process allows individual cases to benefit from shared discovery while preserving each plaintiff’s right to an individual resolution. Historically, MDLs involving pharmaceutical products have resulted in significant settlements after bellwether trials demonstrate the strength of plaintiffs’ claims.
Filing deadlines and procedural requirements continue to evolve as the litigation progresses. If you believe you have a claim, time is of the essence—statutes of limitations may bar claims if you wait too long to pursue legal action.
Who Qualifies for a GLP-1 Stomach Paralysis Lawsuit?
Determining whether you have a valid gastroparesis claim requires meeting several specific criteria. Our gastroparesis attorneys carefully evaluate each potential case based on these qualifying factors.
Eligibility Requirements:
- GLP-1 Drug Use. You must have been prescribed and taken one of the GLP-1 medications listed above (Ozempic, Wegovy, Trulicity, Mounjaro, etc.) according to your doctor’s instructions.
- Confirmed Gastroparesis Diagnosis. You must have been diagnosed with gastroparesis by a qualified physician. This diagnosis should be documented in your medical records.
- Gastric Emptying Study. As required by Judge Marston’s August 2025 ruling, you must have undergone a study showing results consistent with gastroparesis.
- Timing of Diagnosis. Your gastroparesis diagnosis should have occurred during or after your use of the GLP-1 medication, with a temporal relationship suggesting the drug caused or contributed to the condition.
- Severity of Injury. Cases involving more severe outcomes, such as hospitalization, surgical intervention, feeding tube placement, or prolonged symptoms requiring ongoing treatment, generally have stronger claim values.
Factors that Strengthen Your Claim:
- Emergency room visits or hospitalizations for severe vomiting or dehydration
- Documentation of persistent symptoms after discontinuing the medication
- Need for ongoing medical treatment or dietary modifications
- Lost income or inability to work due to symptoms
- Evidence that adequate warnings were not provided about the risks
What if I’m Not Sure I Qualify?
Many potential claimants are uncertain whether their symptoms constitute gastroparesis or whether they have sufficient medical documentation. An experienced Ozempic stomach paralysis lawyer can review your records, help you understand whether additional testing is needed, and advise you on the strength of your potential claim.
Compensation Available in GLP-1 Gastroparesis Cases
Victims of gastroparesis caused by GLP-1 medications may be entitled to substantial financial compensation for the harm they have suffered. The damages available in these cases are designed to make injured patients whole and hold pharmaceutical manufacturers accountable for failing to adequately warn patients. Types of compensation include:
- Economic Damages:
- Medical Expenses: Past and future medical costs, including hospitalizations, emergency room visits, diagnostic testing, medications, nutritional support, and surgical procedures
- Lost Wages: Income lost due to missed work during recovery or ongoing treatment
- Lost Earning Capacity: Reduction in your ability to earn income in the future if gastroparesis has caused permanent disability
- Out-of-Pocket Costs: Travel expenses for medical care, home health aide services, and specialized dietary requirements
- Non-Economic Damages:
- Pain and Suffering: Compensation for the physical discomfort, chronic physical pain, and severe digestive issues you’ve endured
- Emotional Distress: Mental anguish, anxiety, depression, and diminished quality of life resulting from the condition
- Loss of Enjoyment of Life: Inability to participate in activities you once enjoyed, including social meals and physical activities
- Loss of Consortium: For spouses affected by the injury to their partner
In cases where evidence shows that manufacturers acted with gross negligence or willful misconduct, such as concealing known risks or failing to conduct adequate safety testing, courts may award punitive damages designed to punish wrongdoing and deter similar conduct in the future.
What Might My Case Be Worth?
The value of any individual case depends on numerous factors, including:
- Severity and permanence of your gastroparesis
- Extent of medical treatment required
- Impact on your ability to work and earn income
- Duration of symptoms and need for ongoing care
- Strength of medical documentation and causation evidence
- Results of bellwether trials in the MDL
While no attorney can guarantee a specific outcome, cases involving severe, permanent injuries with clear causation typically command higher settlement values or jury verdicts. The multimillion-dollar settlements and verdicts in similar pharmaceutical MDLs demonstrate the potential value of well-documented, serious injury claims.
Why Choose Wagstaff & Cartmell for Your GLP-1 Gastroparesis Stomach Paralysis Lawsuit
When facing a complex pharmaceutical litigation case against some of the world’s largest drug manufacturers, your choice of legal representation can make a critical difference in the outcome of your claim.
Proven MDL Leadership
Wagstaff & Cartmell has earned appointments to leadership positions in multiple high-stakes multidistrict litigations. Our attorneys have served on steering committees and as lead counsel in MDLs involving defective medical devices, dangerous drugs, and consumer products. This experience gives us insider knowledge of how these massive cases are managed and resolved.
Track Record of Results
Our law firm has recovered billions of dollars for injured clients, including:
- $7.25 Billion: Settlement in the transvaginal mesh litigation, one of the largest product liability resolutions in history
- Numerous eight-figure and nine-figure verdicts and settlements pursuing compensation in complex litigation matters
- Recognition as one of the nation’s premier plaintiffs’ law firms in mass tort and class action litigation
Complex Litigation Expertise
GLP-1 gastroparesis cases require sophisticated legal and medical knowledge. Our team works with leading gastroenterologists, pharmacologists, and regulatory experts to build compelling cases demonstrating that manufacturers knew or should have known about the risks of gastroparesis and failed to provide adequate warnings.
Resources to Take on Big Pharma
Pharmaceutical companies have unlimited resources to defend against injury claims. Wagstaff & Cartmell has the financial strength and institutional knowledge to match their efforts, conducting extensive discovery, deposing key witnesses, and retaining world-class expert witnesses to support our clients’ claims.
Personalized Attention
Despite handling thousands of cases in mass tort litigations, we treat each client as an individual with unique circumstances and needs. You’ll have direct access to experienced attorneys who will keep you informed throughout the legal process and fight for maximum compensation in your specific case.
No Fees Unless We Win
We handle GLP-1 gastroparesis cases on a contingency fee basis, meaning you pay no attorney fees unless we recover compensation on your behalf. This ensures that everyone, regardless of financial resources, has access to top-tier legal representation.
Ready to discuss your case? Contact Wagstaff & Cartmell today for a free, confidential consultation with an experienced gastroparesis stomach paralysis lawyer.
GLP-1 Gastroparesis Stomach Paralysis Lawsuit FAQ
Here are some of the questions we receive most often about gastroparesis lawsuits.
The statute of limitations for product liability claims varies by state, typically ranging from one to six years from the date of injury or diagnosis. However, these deadlines can be complex, and waiting too long may bar your claim entirely. We recommend contacting an attorney as soon as possible after diagnosis to ensure your rights are protected.
In MDL cases, additional filing deadlines may apply as the litigation progresses through various phases.
The duration of medication use varies among plaintiffs with valid claims. Some patients developed gastroparesis after only a few weeks or months of use, while others took the weight loss drugs for extended periods. What matters most is the causal connection between the medication and your diagnosis, not the length of time you were on the weight loss drug.
If you have a confirmed gastroparesis diagnosis and emptying study, you may have a valid claim regardless of treatment duration.
Yes. Lawsuits have been filed by patients who took these medications for either approved indication—type 2 diabetes management or weight loss in obese or overweight individuals. The risk of gastroparesis appears to be associated with the weight loss drug’s mechanism of action rather than the reason for prescribing.
Both Ozempic (diabetes) and Wegovy (weight loss) contain the same active ingredient (semaglutide), and patients using either formulation may have valid claims.
Even if your symptoms are partially or fully resolved after discontinuing the GLP-1 weight loss drug, you may still have a compensable injury. The fact that you experienced gastroparesis severe enough to require diagnosis and treatment constitutes an injury for which you may be entitled to compensation. Additionally, many patients continue to experience lingering symptoms or remain at risk for recurrence even after apparent improvement.
The timeline for MDL cases varies considerably depending on numerous factors. Most pharmaceutical MDLs take several years from filing to final resolution. However, cases may settle at various stages, some before bellwether trials, others after trial verdicts demonstrate the value of claims.
While the process requires patience, experienced counsel can help move your case through the system as efficiently as possible while ensuring you receive maximum compensation.
Most product liability cases settle before trial, meaning you likely won’t need to testify in court. However, you may be required to provide a deposition (sworn testimony) during the discovery phase of your case. If your case is selected as a bellwether trial, you would need to participate in trial proceedings.
Your attorney will prepare you thoroughly for any testimony and will be with you throughout the process. Remember that the vast majority of plaintiffs in MDLs never set foot in a courtroom.
The most important evidence includes:
- Records documenting your GLP-1 prescription and usage
- A gastric study with results showing delayed emptying
- Gastroparesis diagnosis from a qualified physician
- Records of hospitalizations, emergency room visits, or treatments related to digestive symptoms
- Pharmacy records showing medication dispensing dates and quantities
- Documentation of lost wages or employment impacts
- Personal journal or notes describing symptom onset and progression
Your attorney can help you gather and organize this evidence. Even if you don’t have all the documentation immediately available, don’t delay contacting a lawyer; medical records can be obtained through the legal process.
Yes. The MDL consolidation is for pretrial purposes only and includes plaintiffs from across the United States. You do not need to live in Pennsylvania to have your case included in MDL 3094. Your case will be coordinated with thousands of others for discovery and pretrial proceedings, but your individual case remains yours. If necessary, your case can be sent back to your home jurisdiction for trial. Wagstaff & Cartmell represents clients nationwide in GLP-1 gastroparesis litigation.
Drug manufacturers often argue that they included sufficient warnings in prescribing information or patient literature. However, legal claims focus on whether the warnings were adequate given what the manufacturer knew or should have known about the risks. Evidence may show that:
- Internal company documents revealed greater risks than disclosed publicly
- Post-marketing surveillance data showed higher-than-expected complication rates
- Warnings buried in lengthy prescribing information weren’t prominent enough
- Direct-to-consumer advertising minimized serious risks while emphasizing benefits
Experienced pharmaceutical litigation attorneys know how to obtain internal documents and expert testimony demonstrating that warnings were inadequate, even when some cautionary language appeared in weight loss drug labeling.
Contact the Legal Team at Wagstaff & Cartmell Today for a Free Consultation
Our experienced Wegovy gastroparesis attorneys are ready to evaluate your case at no cost and with no obligation. We’ll review your medical history, explain your legal options, and help you understand the next steps in pursuing justice.
Don’t let pharmaceutical manufacturers avoid accountability for the harm their products have caused. Join thousands of patients working to pursue compensation for damages, and contact Wagstaff & Cartmell today.